Partnerships

Kamau EM. Roll Back Malaria and the new partnership for Africa’s development: Is there potential for synergistic collaboration in partnerships? Afr J Health Sci 2006;13:22-7.

This synopsis seeks to highlight and promote the enormous potential that exists between these two initiatives that seek to address closely related issues and targeting the same populations at risk within a fairly well defined geographical setting. It also attempts to argue that malaria control, just like HIV control, be given high priority in the New Partnership for Africa’s Development (NEPAD) health agenda, as current statistics indicate that malaria is again on the rise. While much attention and billions of dollars have rightly been given to HIV research, treatment and prevention, malaria, and not HIV, is the region’s leading cause of morbidity and mortality for children under the age of five years. This is the bad news. The good news is that unlike HIV, malaria treatment and prevention are relatively cheap. In addition, there is a payback to fighting malaria; support aimed directly at improving health, rather than poverty reduction, may be a more effective way of helping Africa to thrive. Robust and sustained growth may come to Africa through a mosquito net, Artemisinin-based Combination Therapies (ACTs) or a malaria vaccine, rather that a donor’s cheque for economic development initiatives.  

Editors’ note: We need to get out of our silos, strengthen health systems and look holistically at how we can best address malaria, tuberculosis, and HIV to improve Africa’s development prospects.

No votes yet
  • Share this!